Floatz logo

Everolimus

Hodgkins Lymphoma

OHSU Knight Cancer InstituteSmall moleculePhase 2Dormant
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
95/ 100

Competitive context

141 Active assets in the Hodgkins Lymphoma cohort.

Asset / SponsorPhaseRating
Carboplatin
St. Petersburg State Pavlov Medical University
Phase 2BBB
METHOTREXATE
Therapeutic Advances in Childhood Leukemia Consortium
Phase 3BBB
Camustine
VIVUS LLC
Phase 2BBB
ISOCYCLOPHOSPHAMIDE
St. Petersburg State Pavlov Medical University
Phase 3BBB
Cyclosporin A
City of Hope Medical Center
Phase 3BBB

View all 50 →

Same molecule, other indications

Everolimus is also rated in:

tuberous sclerosisActive
BBB
Indicative · Phase 3
76 / 100
View asset →
hormone receptor-positive breast cancerActive
BBB
Indicative · Phase 4
75 / 100
View asset →
estrogen-receptor positive breast cancerActive
BBB
Indicative · Phase 4
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →